DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2019 Jan 17

PMID 30647800

Citations 4

Authors

Abdelkrim Khadir

Sina Kavalakatt

Mohammed Dehbi

Monira Alarouj

Abdullah Bennakhi

Ali Tiss

Naser Elkum

Affiliations

Soon will be listed here.

Abstract

Background: Cardiovascular disease (CVD) risks persist in patients despite the use of conventional treatments. This might be due to chronic inflammation as reflected in epidemiological studies associating circulating low-grade inflammatory markers with CVD recurrent events. Here, we explored this potential link by assessing plasma dual-specificity phosphatase 1 (DUSP1) levels and comparing them to high-sensitivity CRP (hsCRP) and oxidized low-density lipoprotein (oxLDL) levels and their associations to conventional CVD risk factors in confirmed CVD patients.

Methods: Human adults with reported CVD ( = 207) and controls ( = 70) living in Kuwait were used in this study. Anthropometric and classical biochemical parameters were determined. Plasma levels of DUSP1, oxLDL, and hsCRP were measured using human enzyme-linked immunosorbent assay kits.

Results: DUSP1 and hsCRP plasma levels and their least square means were higher in CVD cases, while oxLDL plasma levels were lower ( < 0.05). Multivariate logistic regression analysis showed that DUSP1 and hsCRP are independently associated with CVD in the studied population, as reflected by 2-fold and 1.5-fold increased risks with increased levels of DUSP1 and hsCRP, respectively. In our study, DUSP1 levels were found to be associated with CVD despite statin treatment and diabetes status ( < 0.05), whereas hsCRP mainly correlated with obesity markers.

Conclusions: Circulating DUSP1 might be a predictor of chronic subclinical inflammation and residual risk in CVD patients, whereas our data suggest that the association between hsCRP and CVD is largely accounted for adiposity risk factors.

Citing Articles

Chronic TNF exposure induces glucocorticoid-like immunosuppression in the alveolar macrophages of aged mice that enhances their susceptibility to pneumonia.

Kruckow K, Murray E, Shayhidin E, Rosenberg A, Bowdish D, Orihuela C Aging Cell. 2024; 23(6):e14133.

PMID: 38459711 PMC: 11296116. DOI: 10.1111/acel.14133.

Phosphatases in toll-like receptors signaling: the unfairly-forgotten.

Lannoy V, Cote-Biron A, Asselin C, Rivard N Cell Commun Signal. 2021; 19(1):10.

PMID: 33494775 PMC: 7829650. DOI: 10.1186/s12964-020-00693-9.

Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators.

Jayaraj R, Azimullah S, Beiram R Saudi J Biol Sci. 2020; 27(2):736-750.

PMID: 32210695 PMC: 6997863. DOI: 10.1016/j.sjbs.2019.12.028.

PR3 levels are impaired in plasma and PBMCs from Arabs with cardiovascular diseases.

Khadir A, Madhu D, Kavalakatt S, Cherian P, Alarouj M, Bennakhi A PLoS One. 2020; 15(1):e0227606.

PMID: 31935243 PMC: 6959567. DOI: 10.1371/journal.pone.0227606.

References

Awazu M, Ishikura K, Hida M, Hoshiya M . Mechanisms of mitogen-activated protein kinase activation in experimental diabetes. J Am Soc Nephrol. 1999; 10(4):738-45. DOI: 10.1681/ASN.V104738. View

Begum N, Ragolia L . High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol Cell Physiol. 2000; 278(1):C81-91. DOI: 10.1152/ajpcell.2000.278.1.C81. View

Hulthe J, Bokemark L, Fagerberg B . Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol. 2001; 21(1):101-7. DOI: 10.1161/01.atv.21.1.101. View

Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R . Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001; 21(5):844-8. DOI: 10.1161/01.atv.21.5.844. View

Albert M, Danielson E, Rifai N, Ridker P . Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286(1):64-70. DOI: 10.1001/jama.286.1.64. View

Hulthe J, Fagerberg B . Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 2002; 22(7):1162-7. DOI: 10.1161/01.atv.0000021150.63480.cd. View

Libby P . Inflammation in atherosclerosis. Nature. 2002; 420(6917):868-74. DOI: 10.1038/nature01323. View

Holvoet P, Harris T, Tracy R, Verhamme P, Newman A, Rubin S . Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol. 2003; 23(8):1444-8. DOI: 10.1161/01.ATV.0000080379.05071.22. View

Ridker P, Cook N . Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004; 109(16):1955-9. DOI: 10.1161/01.CIR.0000125690.80303.A8. View

10.

Lada A, Rudel L . Associations of low density lipoprotein particle composition with atherogenicity. Curr Opin Lipidol. 2004; 15(1):19-24. DOI: 10.1097/00041433-200402000-00005. View

11.

Athyros V, Mikhailidis D, Papageorgiou A, Bouloukos V, Pehlivanidis A, Symeonidis A . Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens. 2004; 18(11):781-8. DOI: 10.1038/sj.jhh.1001748. View

12.

Davignon J . Emphasis on pleiotropic effects, a new paradigm shift?. Coron Artery Dis. 2004; 15(5):223-5. DOI: 10.1097/01.mca.0000131571.06897.da. View

13.

Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J . Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med. 2004; 256(5):413-20. DOI: 10.1111/j.1365-2796.2004.01402.x. View

14.

Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W . Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation. 2005; 112(5):651-7. DOI: 10.1161/CIRCULATIONAHA.104.529297. View

15.

Kang J, Patino W, Matoba S, Hwang P . Genomic analysis of circulating cells: a window into atherosclerosis. Trends Cardiovasc Med. 2006; 16(5):163-8. PMC: 1553568. DOI: 10.1016/j.tcm.2006.03.006. View

16.

Albert M, Ridker P . C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference?. Circulation. 2006; 114(5):e67-74. DOI: 10.1161/CIRCULATIONAHA.106.613570. View

17.

Weng Y, Shen F, Li J, Shen Y, Zhang X . Expression changes of mitogen-activated protein kinase phosphatase-1 (MKP-1) in myocardium of streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes. 2007; 115(7):455-60. DOI: 10.1055/s-2007-973060. View

18.

Holvoet P, Lee D, Steffes M, Gross M, Jacobs Jr D . Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA. 2008; 299(19):2287-93. PMC: 2562739. DOI: 10.1001/jama.299.19.2287. View

19.

Langlois M, Rietzschel E, De Buyzere M, De Bacquer D, Bekaert S, Blaton V . Femoral plaques confound the association of circulating oxidized low-density lipoprotein with carotid atherosclerosis in a general population aged 35 to 55 years: the Asklepios Study. Arterioscler Thromb Vasc Biol. 2008; 28(8):1563-8. DOI: 10.1161/ATVBAHA.108.167346. View

20.

Zakkar M, Chaudhury H, Sandvik G, Enesa K, Luong L, Cuhlmann S . Increased endothelial mitogen-activated protein kinase phosphatase-1 expression suppresses proinflammatory activation at sites that are resistant to atherosclerosis. Circ Res. 2008; 103(7):726-32. DOI: 10.1161/CIRCRESAHA.108.183913. View